zydus lifesciences

  1. S

    Zydus Launches Generic Anti-Parasitic and Leprosy Treatments in the US

    New Delhi, February 28 Zydus Lifesciences announced on Saturday that it has received approval from the US health regulator to market generic anti-parasitic and leprosy medications.The company has received final approvals from the US Food and Drug Administration (USFDA) for Ivermectin Tablets...
  2. A

    Zydus Launches Biosimilar for Diabetes-Related Visual Impairment

    New Delhi, February 19 Zydus Lifesciences announced on Thursday that it has launched its first biosimilar, developed indigenously, for the treatment of visual impairment.Anyra, the country's first biosimilar of Aflibercept 2 mg, is indicated for the treatment of visual impairment caused by...
  3. S

    New Device Aims to Improve Breathing for COPD and Asthma Patients in India

    New Delhi, February 17 Zydus Lifesciences announced on Tuesday that it has launched a device to help clear congestion, support effective mucus clearance, and improve breathing in patients with COPD, asthma, and bronchiectasis.The company has launched PEPAIR, India's first affordable...
  4. I

    Zydus Settles Patent Dispute for Overactive Bladder Medication

    New Delhi, February 12 Zydus Lifesciences announced on Thursday that it will pay USD 120 million to Astellas Pharma to settle a patent dispute over a medication for treating an overactive bladder.Zydus Pharmaceuticals USA, Inc, a wholly-owned subsidiary of the company, has entered into a...
  5. D

    Supreme Court Defers Restraint on Zydus's Cancer Drug Biosimilar

    New Delhi, February 11 The Supreme Court on Wednesday refused to restrain Zydus Lifesciences from selling its affordable, generic biosimilar of Nivolumab, a life-saving cancer drug registered by Bristol Myers Squibb (BMS).A bench of Chief Justice Surya Kant and Justice Joymalya Bagchi was...
  6. A

    Pharmaceutical Growth Drives Zydus Lifesciences' Net Profit Increase

    New Delhi, February 9 Zydus Lifesciences Ltd on Monday reported a 1.81 per cent increase in consolidated net profit at Rs 1,042.1 crore for the quarter ended December 31, 2025.The company had posted a consolidated net profit of Rs 1,023.5 crore in the corresponding quarter of the previous...
Back
Top